Partnering and Licensing Opportunities
Symphogen is maturing a pipeline of recombinant antibody products within hematology, infectious disease and oncology on its own and together with partners. Oncology, in particular, has become a focus for Symphogen due to the remarkable results its team of scientists has achieved in a field of great medical need, and the company continues to strengthen its oncology activities through partnerships and acquisitions.
For indications outside oncology, Symphogen is also actively seeking value-adding collaborative partnerships with biotech and pharmaceutical companies to enhance the commercialization opportunities for its other pipeline products and to leverage the potential of the company’s proprietary antibody technologies and strong antibody capabilities.
Symphogen has developed into a mature late-stage company through a united and committed effort from many people within and outside the company including the company’s partners. Symphogen’s technologies and expertise within the antibody field have in the process been validated through its corporate partnerships with pharmaceutical companies in the US, Europe, and Japan.
- Partners can access unique technology for generation of antibodies, which are superior in many ways to those generated by competing platforms.
- Symphogen’s partnering strategy is flexible; the company is interested in discussing funded collaborations as well as shared risk (co-development) relationships.
- Symphogen’s proprietary discovery engine, Symplex™, is available for licensing to companies seeking a strong antibody discovery tool for therapeutic and diagnostic applications.
- Symphogen’s proprietary polyclonal manufacturing platform, Sympress™, is available for licensing to companies looking to, cost-efficiently and reproducibly, produce recombinant polyclonal products or mixtures of monoclonal antibodies.
- Symphogen has a dominant, long-term IP position for its antibody discovery, manufacturing, and characterization platforms.
